Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diagnostic Pathology
Published in: Diagnostic Pathology 1/2020

Open Access 01-12-2020 | Computed Tomography | Case Report

Orbital involvement by NUT midline carcinoma: new presentation and encouraging outcome managed by radiotherapy combined with tyrosine kinase inhibitor: a case report

Authors: Peiwei Chai, Chuandi Zhou, Renbing Jia, Yefei Wang

Published in: Diagnostic Pathology | Issue 1/2020

Login to get access

Abstract

Background

NUT midline carcinoma (NMC) is a poorly differentiated squamous cancer with a median survival at less than 7 months. NMC is resistant to conventional chemotherapies and characterized by rearrangement of the NUT gene.

Case presentation

Here, we described a patient who initially presented with epiphora, and an orbit involved NMC. In addition, we for the first time demonstrated that local radiotherapy combined with tyrosine kinase inhibitor (TKI) could significantly inhibit tumor progression in orbital involvement by NMC.

Conclusions

Our study for the first time described an orbit involved NMC patient initially presented with epiphora. In addition, we provided an alternative to the management of orbit involved NMC.
Literature
1.
Chau NG, Hurwitz S, Mitchell CM, et al. Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck. Cancer. 2016;122:3632–40.CrossRef
2.
3.
Beesley AH, Stirnweiss A, Ferrari E, et al. Comparative drug screening in NUT midline carcinoma. Br J Cancer. 2014;110:1189–98.CrossRef
4.
Bauer DE, Mitchell CM, Strait KM, et al. Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res. 2012;18:5773–9.CrossRef
5.
Wang R, Cao XJ, Kulej K, et al. Uncovering BRD4 hyperphosphorylation associated with cellular transformation in NUT midline carcinoma. Proc Natl Acad Sci U S A. 2017;114:E5352–61.CrossRef
6.
D’Souza JN, Notz G, Bogdasarian RN, et al. Orbital involvement by NUT midline carcinoma. Ophthalmic Plast Reconstr Surg. 2015;31:e147–50.CrossRef
7.
Bragelmann J, Dammert MA, Dietlein F, et al. Systematic kinase inhibitor profiling identifies CDK9 as a synthetic lethal target in NUT midline carcinoma. Cell Rep. 2017;20:2833–45.CrossRef
8.
Gokmen-Polar Y, Kesler K, Loehrer PJ Sr, et al. NUT midline carcinoma masquerading as a Thymic carcinoma. J Clin Oncol. 2016;34:e126–9.CrossRef
9.
Teo M, Crotty P, O'Sullivan M, et al. NUT midline carcinoma in a young woman. J Clin Oncol. 2011;29:e336–9.CrossRef
10.
Lewin J, Soria JC, Stathis A, et al. Phase Ib trial with Birabresib, a small-molecule inhibitor of Bromodomain and Extraterminal proteins, in patients with selected advanced solid tumors. J Clin Oncol. 2018;36:3007–14.CrossRef
11.
Revach OY, Sandler O, Samuels Y, et al. Cross-talk between receptor tyrosine kinases AXL and ERBB3 regulates Invadopodia formation in melanoma cells. Cancer Res. 2019;79:2634–48.CrossRef
12.
Leopold AV, Chernov KG, Shemetov AA, et al. Neurotrophin receptor tyrosine kinases regulated with near-infrared light. Nat Commun. 2019;10:1129.CrossRef
13.
Wahl DR, Lawrence TS. No sugar added: a new strategy to inhibit Glioblastoma receptor tyrosine kinases. Clin Cancer Res. 2019;25:455–6.CrossRef
14.
Chen XZ. Anlotinib for refractory advanced non-small cell lung Cancer in China. JAMA Oncol. 2019;5:116–7.CrossRef
15.
Han B, Li K, Wang Q, et al. Effect of Anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung Cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 2018;4:1569–75.CrossRef
Metadata
Title
Orbital involvement by NUT midline carcinoma: new presentation and encouraging outcome managed by radiotherapy combined with tyrosine kinase inhibitor: a case report
Authors
Peiwei Chai
Chuandi Zhou
Renbing Jia
Yefei Wang
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2020
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/s13000-019-0922-1

Other articles of this Issue 1/2020

Diagnostic Pathology 1/2020 Go to the issue

Research

Deep learning-based image analysis methods for brightfield-acquired multiplex immunohistochemistry images

Research

Clinicopathologic features of infection-related glomerulonephritis with IgA deposits: a French Nationwide study

Research

High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas

Research

Angiogenesis in mammary Paget disease: histopathological analyses of blood vessel density and angiogenic factors

Case Report

Next generation sequencing to decipher concurrent loss of PMS2 and MSH6 in colorectal cancer

Commentary

Spotlight on Ki67 as a prognostic marker in early breast cancer: all that glitters may not be gold